Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1995 2
1996 2
1998 2
1999 3
2000 3
2002 5
2003 5
2004 5
2005 1
2007 2
2008 1
2009 1
2010 1
2011 1
2013 3
2014 2
2015 4
2017 1
2018 1
2019 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen BT, Hartmann AM, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller FJ, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus CD. Bastian L, et al. Among authors: schneller f. Blood. 2024 Apr 4;143(14):1391-1398. doi: 10.1182/blood.2023021752. Blood. 2024. PMID: 38153913 Free PMC article.
Biotherapy of chronic myelogenous leukemia.
Aulitzky WE, Peschel C, Schneller F, Huber C. Aulitzky WE, et al. Among authors: schneller f. Ann Hematol. 1995 Mar;70(3):113-20. doi: 10.1007/BF01682030. Ann Hematol. 1995. PMID: 7718640 Review.
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia.
Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J, Rieder H, Gökbuget N, Hoelzer D, Thiel E. Burmeister T, et al. Among authors: schneller f. Haematologica. 2007 Dec;92(12):1699-702. doi: 10.3324/haematol.11737. Haematologica. 2007. PMID: 18055996 Free article.
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Brüggemann M, Gökbuget N, Baldus CD. Neumann M, et al. Among authors: schneller f. Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264-0. Online ahead of print. Leukemia. 2024. PMID: 38744920
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W, Lowe J, Mattson P, Richard Trout J, Huhn RD, Gargano M, Patchen ML, Walsh R, Trinh MM, Dupuis M, Schneller F. Engel-Riedel W, et al. Among authors: schneller f. J Immunother Cancer. 2018 Feb 27;6(1):16. doi: 10.1186/s40425-018-0324-z. J Immunother Cancer. 2018. PMID: 29486797 Free PMC article. Clinical Trial.
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M, Sadjadian P, Kollmeier J, Lowe J, Mattson P, Trout JR, Gargano M, Patchen ML, Walsh R, Beliveau M, Marier JF, Bose N, Gorden K, Schneller F 3rd. Thomas M, et al. Among authors: schneller f 3rd. Invest New Drugs. 2017 Jun;35(3):345-358. doi: 10.1007/s10637-017-0450-3. Epub 2017 Mar 16. Invest New Drugs. 2017. PMID: 28303530 Free PMC article. Clinical Trial.
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Ramalingam S, et al. Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19. Ann Oncol. 2013. PMID: 24050956 Free article. Clinical Trial.
[Interferon-alpha in therapy of malignant hemoblastoses].
Schuler M, Aulitzky WE, Schneller F, Peschel C, Huber C. Schuler M, et al. Among authors: schneller f. Internist (Berl). 1995 Dec;36(12):1133-8. Internist (Berl). 1995. PMID: 8567218 Review. German. No abstract available.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD. Sebastian M, et al. Among authors: schneller f. Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15. Cancer Immunol Immunother. 2019. PMID: 30770959 Free PMC article. Clinical Trial.
46 results